In a recent trial by Johnson & Johnson involving 45,000 volunteers, the efficacy of their single-dose, adenoviral-vectored, Ad26

  • Post author:
  • Post category:COMT

In a recent trial by Johnson & Johnson involving 45,000 volunteers, the efficacy of their single-dose, adenoviral-vectored, Ad26.COV2.S vaccine in conferring protection against moderate to severe COVID-19 was 72% in…

Continue ReadingIn a recent trial by Johnson & Johnson involving 45,000 volunteers, the efficacy of their single-dose, adenoviral-vectored, Ad26

The proposed approach holds several advantages for LN targeted tumor therapy: high uptake in the TDLN, ability to present the therapeutic substance to cancer cells in its natural form, and low toxicity to local LN tissue

  • Post author:
  • Post category:COMT

The proposed approach holds several advantages for LN targeted tumor therapy: high uptake in the TDLN, ability to present the therapeutic substance to cancer cells in its natural form, and…

Continue ReadingThe proposed approach holds several advantages for LN targeted tumor therapy: high uptake in the TDLN, ability to present the therapeutic substance to cancer cells in its natural form, and low toxicity to local LN tissue